Blog / William Blair Interview Questions
Firm-Specific Prep
William Blair Interview Questions
These are real technical questions asked in recent William Blair interviews, sourced directly from candidates who went through the process — not a generic guide. Below: what to expect, worked answers to the most representative questions, and common mistakes that trip candidates up.
What William Blair's interview process actually looks like
William Blair's middle-market generalist rounds carry a healthcare lean — probability-of-success-weighted NPV for pre-revenue biotech alongside standard diluted share count and LBO candidate characteristics questions.
Real questions asked in recent William Blair interviews
Question: An interviewer tells you 'more debt' is the wrong answer when you're asked what makes an LBO candidate attractive. What's the better way to think about the right amount of leverage?
How to answer it: More leverage amplifies returns when things go well, but it also amplifies risk, since higher debt means higher fixed interest and amortization payments that must be met regardless of how the business performs, so the right amount of leverage isn't the maximum a lender will provide, it's the amount the company's cash flow can comfortably service through a downside scenario, not just the base case. A good LBO candidate is attractive because of the underlying business quality, stable cash flows, defensible market position, room for operational improvement, not because it can support a lot of debt; the debt capacity is a consequence of a good business, not the reason it's a good investment. Sponsors typically size leverage off a target credit statistic, like debt to EBITDA or an interest coverage ratio, calibrated against a stress-tested downside case, since a deal that only works in the base case and breaches covenants or risks default in a mild downturn isn't actually a well-underwritten LBO, no matter how attractive the base-case IRR looks.
Common mistake: Treating maximum available leverage as inherently attractive rather than sizing debt against a stress-tested downside scenario
Question: How do you value a pre-revenue biotech company that has one drug candidate in Phase 2 trials, and what does 'probability of success' mean in that context?
How to answer it: A pre-revenue biotech with a single pipeline asset is typically valued using a risk-adjusted, or probability-weighted, NPV approach: build out the potential peak sales and cash flow the drug could generate if it's approved and commercialized, discount those cash flows back to get an unadjusted NPV, then multiply that NPV by the probability of success, the statistical likelihood the drug actually makes it through remaining trials and regulatory approval given its current phase and indication. Probability of success climbs at each successive trial phase, historical industry data shows drugs in Phase 2 have a meaningfully lower probability of eventually reaching approval than drugs already in Phase 3, so where the asset sits in the pipeline materially changes its risk-adjusted value even before considering the science itself. An orphan drug designation, for a treatment targeting a rare disease, can meaningfully increase probability of success and speed to approval since it typically comes with regulatory incentives like extended market exclusivity, tax credits, and sometimes a smaller required trial population, all of which reduce both commercial and regulatory risk relative to a non-orphan indication.
Common mistake: Valuing a pre-revenue biotech drug candidate using an unadjusted NPV without applying a probability of success discount for trial and regulatory risk
Also reported from recent interviews at this firm:
- A company has 50 million basic shares, options for 4 million shares at a $15 strike, and convertible notes convertible into 2 million shares at an effective conversion price of $22. The current stock price is $18. How do you handle diluted shares?
- Walk through how you'd calculate WACC for a private, recently-LBO'd portfolio company with no public equity comps of its own.
Full explanations and common mistakes for these — plus the rest of our Firm Specific bank — are in the app.
How to prepare specifically for William Blair
Generic IB prep guides cover the fundamentals every bank tests, but firm-specific patterns like the ones above only show up when you're practicing against real, recently-reported questions rather than a static 400-question PDF everyone else is also using. ApexIB's Firm Specific question bank is built directly from questions candidates report after their actual interviews — including William Blair — with AI grading and full explanations, not just a list.
Frequently asked questions
Does William Blair ask healthcare and biotech-specific questions?
Often, yes — given the firm's healthcare practice strength, expect questions on risk-adjusted biotech valuation alongside standard generalist technicals.
Where do these questions come from?
Directly from candidates who interviewed at William Blair and reported their questions afterward, not from a generic template applied to every firm.
Related articles